Discover Research Studies

This is a trial testing whether a medication called AMX0035 will help improve metabolism and blood sugar control in adults with Type 1 Diabetes. Participants will take one packet of AMX0035 (mixed with water) twice a day, for 24 weeks. Before starting and after completing the treatment, participants will undergo blood and urine tests, body scans (DEXA and MRI), an insulin sensitivity test, a metabolism test, heart function tests, and muscle and fat biopsies. While receiving treatment, participants will come in for two in person visits with an ECG to monitor blood tests and side effects, and have one phone call visit.

This study is testing a new investigational therapy called CNP-103 (an IV infusion) for people recently diagnosed with type 1 diabetes (T1D). The study will evaluate whether CNP-103 is safe and whether it may help the body preserve its own ability to produce insulin. While tools like insulin pumps and continuous glucose monitors have improved diabetes management, protecting the body's remaining insulin-producing cells is still considered the best possible approach to managing T1D.

This study is testing whether a higher dose of dulaglutide (Trulicity®), a medication already approved for adults with type 2 diabetes, is safe and effective for children. Dulaglutide is given as an injection under the skin. This study will evaluate the 4.5 mg dose specifically in children.

This study examines how semaglutide, a weekly injectable medication, affects heart function, kidney function, and insulin sensitivity in adults with type 1 diabetes over an 8-month treatment period.

This study examines kidney tissue and biological samples to better understand how kidney conditions like acute kidney injury and chronic kidney disease differ from person to person with the goal of discovering more targeted treatments.

This study follows youth through puberty over two years to research how puberty may affect kidney health and diabetes risk factors. This study involves three two day study visits over the course of two years (two days at baseline, and two additional at each year). The study visits entail a kidney MRI, a DEXA scan, and IV placement for kidney testing and insulin tolerance testing.

A large randomized clinical trial testing whether the drug sotagliflozin can slow kidney function decline in people with type 1 diabetes and moderate-to-severe diabetic kidney disease. Participants are monitored over three years with CGM data, blood/urine tests, and ketone tracking.

This study evaluates whether inspiratory muscle strength training can reduce blood pressure and improve cardiovascular and kidney health in youth at risk for type 2 diabetes. It involves a 12-week breathing intervention with physiological and vascular assessments.

A placebo-controlled trial examining the combined effects of automated insulin delivery and metformin on metabolic and cardiovascular health in youth with type 1 diabetes. Participants undergo repeated assessments of insulin sensitivity and body composition over four months.

This study tests whether weekly injections of GLP‑1 medicines (retatrutide or tirzepatide) can prevent worsening of high‑risk fatty liver disease.

This study looks at how a baby’s brain and early nutrition affect weight and growth in infants of mothers who had gestational diabetes.

This study tests whether a short course of Anti‑thymocyte Globulin (an immune‑targeting therapy) followed by either Adalimumab (an anti‑inflammatory biologic) or Verapamil (a repurposed heart medication) can help people newly diagnosed with Type 1 diabetes keep making their own insulin longer and better control blood sugar.

This Phase 3 trial tests whether adding the investigational drug cadisegliatin to insulin can reduce low‑blood‑sugar episodes in people with Type 1 diabetes

This study tests whether a new bedtime injection (ZT‑01) can raise a natural sugar‑protecting hormone and reduce nighttime low blood sugars in adults with Type 1 diabetes